Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 3, 2018. The document reports the results of a General Meeting of shareholders held on that date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
The primary material event reported is the shareholder approval of a resolution to approve the buyout of Novartis' interest in GlaxoSmithKline Consumer Healthcare Holdings Limited. The voting results were as follows:
- Total Votes Cast: 3,888,405,243
- Votes For: 3,886,722,476 (99.96%)
- Votes Against: 1,682,767 (0.04%)
- Votes Withheld: 21,712,896
Participation metrics indicate that 78.84% of the issued share capital (excluding Treasury Shares) was represented by votes cast or withheld. The total shareholder population was 112,326, with 7,976 proxies lodged (7.10% of shareholders).
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. It strictly confirms the passage of the resolution and notes that the full text is available in the Circular to Shareholders on the company website.
Key Facts for Investor Verification
- Shareholders overwhelmingly approved (99.96%) the buyout of Novartis' stake in GSK Consumer Healthcare.
- The resolution was passed to comply with Chapter 11 of the Listing Rules of the Financial Conduct Authority.
- Approximately 78.84% of the issued share capital participated in the vote.
- Financial performance data is not included in this specific filing.